Sai-Hong Ignatius Ou, MD, PhD
In non–small cell lung cancer (NSCLC), KRAS
G12 mutations have been historically difficult to target, and research efforts dedicated to the development of effective targeted therapies for NRG1
fusions have not been successful. However, several biopharmaceutical companies are in the early stages of addressing that challenge, explained Sai-Hong I. Ou, MD, PhD.
... to read the full story